1. Overview
   1.1 Components of Blood Plasma
   1.2 Functions of Blood Plasma
   1.3 Collection and Extraction of Plasma
      1.3.1 Plasma Collection
      1.3.2 Plasma Extraction
      1.3.3 Plasma Fractionation Yield
      1.3.4 Plasma Usage

2. Blood Plasma Market Structure
   2.1 Global Blood Plasma Market
      - Market Value
      - Market Segments
      2.1.1 Plasma Industry Cost Structure
      2.1.2 Plasma Market of the US
   2.2 Global IVIG Market
      - Market Value
      - Demand & Supply
      - Breakdown by Region
      2.2.1 IVIG Market of the US
   2.3 Global Hemophilia Market
      - Hemophilia A
      - Hemophilia B
      2.3.1 FVIII Market of the US
   2.4 Albumin Market
      2.4.1 Albumin Market of China and the US

3. Market Dynamics
   3.1 Key Trends
      3.1.1 Kinetics of Plasma-collection Industry
      3.1.2 Reimbursement
      3.1.3 Growing Penetration of rFVIII Products in Emerging Markets – Opportunity for Manufacturers
      3.1.4 A1PI Deficiency- Confined to Prevention only
   3.2 Industry Developments
      3.2.1 Improved Biological Molecule Formulations
      3.2.2 Baxter’s Phase I Clinical Trial of Treatment for Hemophilia A
   3.3 Growth Drivers
      3.3.1 Increasing New Patient Registration for Hemophilia Treatment
      3.3.2 Increased Usage of Plasma Derived Products
      3.3.3 Rising Healthcare Expenditure
      3.3.4 Higher Spending on Medicines
      3.3.5 Rising Demand for Better Healthcare Options
      3.3.6 Launch of NMEs (New Molecular Entities)
      3.3.7 Growing Ageing Population (+60 Years)
      3.3.8 Rising Male Population
      3.3.9 Ameliorating Economic Conditions
   3.4 Challenges
3.4.1 Increasing regulation in the plasma-collection industry
3.4.2 Escalating Price Pressure
3.4.3 Constrained Plasma Fractionation Capacity
3.4.4 Misdiagnosis of the Disease

4. Competitive Landscape
   4.1 Blood Plasma Market Rivalry
   4.2 Plasma Derivatives Market Contention
      4.2.1 Immunoglobulins
         -IVIG Market of Europe
         -IVIG Market of North America
         -IVIG Market of the US
      4.2.2 Albumin Market
         -Albumin Market of the US
         -Albumin Market of China
      4.2.3 Other Products

5. Company Profiles
   5.1 Baxter International Inc.
      5.1.1 Business Overview
      5.1.2 Financial Overview
      5.1.3 Business Strategies
         -Focus on Investment in R&D
         -Growth through Sustainable Development
   5.2 Grifols
      5.2.1 Business Overview
      5.2.2 Financial Overview
      5.2.3 Business Strategies
         -Expansion in Other Geographic Regions
         -Growth through Mergers and Acquisitions
   5.3 CSL Limited
      5.3.1 Business Overview
      5.3.2 Financial Overview
      5.3.3 Business Strategies
         -Focus on R&D
         -Expanding Product Portfolio
   5.4 Octapharma
      5.4.1 Business Overview
      5.4.2 Financial Overview
      5.4.3 Business Strategies
         -Focus on Innovation
         -Expansion of Production Facilities

6. Market Outlook
   6.1 Market Forecast
   6.2 Forecast Methodology
      6.2.1 Dependent and Independent Variables
      6.2.2 Correlation Analysis
      6.2.3 Regression Analysis
List of Charts

- Plasma Extraction from Donated Blood (Recovered Plasma)
- Plasmapheresis (Source Plasma)
- Global Plasma Market Share by Product (2011)
- Manufacturing Cost Split for Plasma Fractionation (September 2011)
- Plasma Derivative Sales in the US (2005-2011)
- Global IVIG Demand and Supply (2007-2012E)
- Global IVIG Market Share by Geography (2011)
- IVIG Use by Indication
- Sales of IVIG in the US (2001-2011)
- Global Hemophilia Treatment Market Revenues (2006-2012)
- Global FIX Market (2011)
- Annual Global Sales of NovoSeven (2007-2011)
- Monthly Distribution of FVIII in the US (January 2011-September 2012)
- Albumin Market Size of the US and China
- Albumin Price across US and China
- China’s Plasma Protein Market Growth (October 2012)
- Monthly Distribution of Albumin 25% in the US (January 2011-September 2012)
- Monthly Distribution of Albumin 25% in the US (January 2011-September 2012)
- Licensed Plasma Centers in the US and their profitability (FY06-FY11)
- A1PI Statistics of North America and EU
- Per Capita Usage of FVIII in Developed Countries
- Per Capita Usage of FVIII in Developing Countries
- Per Capita FIX Usage in Developed Economies
- Per Capita FIX Usage in Emerging Economies
- Global Spending on Medicines (2006-2016E)
- Global Spending on Medicine Share by Region (2006-2016E)
- The US Spending on Medicine (2007-2016E)
- Japan’s Spending on Medicine (2007-2016E)
- Biotechnology Therapeutics Under Development (2011)
- Global Male Population (2005-2014F)
- Global GDP (2001-2011)
- World GDP per Capita (2005-2011)
- Global Plasma Market Share by Company (2011)
- Aligned PCCs vs. independent PCCs Share in the US (2011)
- Europe’s IVIG Market Share (2011)
- North America’s IVIG Market Share (2011)
- US IVIG Market (2011)
China’s Albumin Market (2011-12)
Product Rivalry in the US (2011)
Baxter’s Revenue by Business Segments (2011)
Baxter’s Revenues and Net Income (2008-2011)
Grifols Revenue Share by Business Segments (2011)
Grifols’ Revenues & Profits (2008-2011)
CSL’s Revenue Share by Major Products (2011-12)
CSL’s Revenues and Net Profit (2008/09-2011/12)
Octapharma’s Net Sales and Net Profit (2008-2011)

List of Tables
- Constituents of Blood Plasma
- Recovered plasma vs. Source plasma
- Output per Liter of Plasma
- Breakdown of US IVIG usage by Patient Share & Volume Share by Indication
- Breakdown of US SCIG and IVIG Usage by Volume Share (FY11)
- US Centre for Medicare and Medicaid (CMS) Reimbursement
- Conversion to Recombinant Factor VIII Products in Selected Countries (2010)
- A1PI Products
- Long Acting FIX & FVIII under Late-Stage Development
- Extended Half Life rFVIII Agents
- Extended Half Life rFIX Agents
- Patients Worldwide Waiting for Better Treatment Options (2011)
- Global Availability of NMEs (2011)
- IVIG Product Characteristics
- Dependent & Independent Variables (2007-2011)
- Correlation Matrix
- Regression Coefficients Output